Ozempic Cost 2026: Savings Card, Without Insurance & the Cheapest Path

Path 1: Ozempic Savings Card — $25/month with commercial insurance

The Ozempic Savings Card is Novo Nordisk's manufacturer copay assistance program. Eligible patients with commercial insurance that covers Ozempic pay as low as $25 per month for a 28-day supply, subject to monthly and annual savings caps. This is the cheapest legitimate path for most insured type 2 diabetes patients whose plan includes Ozempic on formulary.

Eligibility:

• Commercial (private) insurance that covers Ozempic on its formulary
• US resident with valid prescription for Ozempic
• Prescription is for an FDA-approved indication (type 2 diabetes, or one of the approved cardiovascular/kidney sub-indications)
• NOT eligible: Medicare, Medicaid, VA, Tricare, or any other federal/state insurance enrollee — federal anti-kickback law blocks savings-card use for these plans
• NOT eligible: commercial insurance that does not cover Ozempic (the discount only applies on top of a covering plan)

Apply at ozempic.com. Once approved, the card is presented at the pharmacy and the discount applies automatically when the prescription is filled. Monthly and annual savings caps mean the $25 figure is the floor — patients with extremely high copays may still pay more, though for most insured patients $25 is the actual number.

Path 2: NovoCare cash-pay — $499/month for adults with type 2 diabetes

NovoCare is Novo Nordisk's direct-to-patient program, launched in part to give cash-pay patients with type 2 diabetes a more affordable Ozempic path. NovoCare sells brand-name Ozempic at a flat $499/month for eligible adult T2D patients without insurance coverage that applies.

How it works:

• Visit novocare.com to start the cash-pay enrollment
• Confirm eligibility (adult, type 2 diabetes diagnosis, US resident, cash-pay — not using insurance)
• Get prescribed Ozempic through your own clinician or a partner telehealth network
• $499 covers the medication; injection pens come ready to use

NovoCare is meaningfully cheaper than retail cash-pay (~$1,000) and is the right path for patients who want a brand-Novo product but don't qualify for the savings card — typically because they have no insurance, have federal insurance that won't cover, or have commercial insurance that doesn't include Ozempic on formulary. Eligibility is restricted to adults with type 2 diabetes; off-label weight-loss use is not supported on this pathway.

Path 3: Compounded semaglutide — $150-250/month, the cheapest path

Compounded semaglutide is the same active ingredient as Ozempic (and as Wegovy and Rybelsus), prepared by a state-licensed 503A pharmacy under FDA-permitted conditions. Telehealth programs like Brightmeds, GobyMeds, and Henry Meds offer compounded semaglutide at $150-250/month for cash-pay patients without insurance.

Important caveats:

• Compounded semaglutide is NOT FDA-approved as a standalone product
• It's legal when prepared by a registered 503A or 503B pharmacy under specific FDA conditions
• Quality varies by pharmacy — verify state board of pharmacy licensure before ordering
• The FDA semaglutide shortage status has shifted multiple times in recent years; ongoing compounding requires careful pharmacy compliance with state and federal rules
• Compounded semaglutide is prescribed by a clinician through the telehealth program, not directly by the pharmacy

For cash-pay patients, compounded semaglutide is the cheapest legitimate semaglutide path — typically less than half the NovoCare cash-pay rate. The trade-off is product format (most compounded semaglutide ships as a vial requiring self-injection with a separate syringe, rather than a prefilled pen) and reduced uniformity vs the brand product. For most uninsured patients, the cost savings make this the right starting point.

Path 4: Patient Assistance Program (NovoCare Foundation) — income-qualified uninsured

The NovoCare Patient Assistance Program, administered through Novo Nordisk's foundation, provides free Ozempic to income-qualified uninsured patients. Eligibility is typically capped at household income at or below 400% of the federal poverty level. Application requires prescriber participation (your clinician completes part of the paperwork) and processing takes 4-8 weeks. Once approved, medication ships periodically through the participating prescriber.

For most uninsured patients, NovoCare cash-pay ($499) is faster than navigating PAP eligibility. The PAP remains the right path for patients who genuinely cannot afford even the $499 cash-pay rate and meet the income criteria. Note: PAPs do not cover off-label use — applications for non-T2D indications are typically denied.

Path 5: GoodRx + retail pharmacy — modest savings on retail

GoodRx coupons exist for Ozempic at most major retail pharmacies (CVS, Walgreens, Walmart, Costco). Discounts run 5-15% off retail in most markets, dropping cash-pay from roughly $1,000 to $850-950/month with a code applied at the pharmacy counter.

For most patients, GoodRx is the wrong path for Ozempic — the savings are too small relative to the Ozempic Savings Card ($25 with eligibility), NovoCare cash-pay ($499), or compounded semaglutide ($150-250). GoodRx makes sense only when none of the cheaper paths is available, which is a narrow case.

Path 6: Retail cash-pay — almost never the right choice

Brand-name Ozempic at retail without insurance: approximately $1,000/month. This is Novo Nordisk's wholesale list price translated through the retail pharmacy markup. For uninsured cash-pay patients, this path is dominated by every other option in this guide. The only justification is unavailability of NovoCare and compounded options in your state — a narrow case that should be revisited every few months as the landscape evolves.

When Ozempic isn't the right Rx

Ozempic is FDA-approved for type 2 diabetes, not for weight management. If you're pursuing semaglutide specifically for weight loss without a T2D diagnosis, the right product is usually Wegovy — the higher-dose semaglutide product that IS FDA-approved for chronic weight management. Insurance is far more likely to cover Wegovy for an on-label weight-loss indication than Ozempic off-label, and the Wegovy Savings Card applies for eligible commercial-insurance patients.

If tirzepatide (the active ingredient in Mounjaro for T2D and Zepbound for weight management) is a fit, that's a different molecule with different cost economics — typically slightly cheaper retail for Zepbound ($1,059) and a competitive LillyDirect cash-pay rate ($399 for vials). See our Zepbound cost guide for the full breakdown.

Patients pursuing semaglutide for weight loss off-label should expect: no insurance coverage, no savings card eligibility, full retail or compounded pricing only. In almost every case, switching to Wegovy (for weight loss) or sticking with Ozempic (only if you have T2D) is the right move.

Common Ozempic cost mistakes

• Assuming the savings card works on any insurance. It only works with commercial (private) insurance that already covers Ozempic. Federal-plan enrollees and uninsured patients can't use it.
• Trying to use Medicare to cover off-label weight-loss use. Medicare Part D statutorily excludes weight-management drugs. Ozempic is covered for T2D only.
• Paying retail cash-pay without checking NovoCare. If you have a T2D diagnosis and no insurance applying, NovoCare's $499/month is half of retail.
• Settling for GoodRx as the "cheap" path. GoodRx typically only saves 5-15% on Ozempic. NovoCare, compounded semaglutide, and the savings card are all dramatically cheaper.
• Ordering compounded semaglutide from an unverified pharmacy. Verify state board of pharmacy licensure before ordering. Telehealth programs that won't disclose their pharmacy partner are a red flag.
• Asking for Ozempic when Wegovy is the right product. If the indication is weight loss without diabetes, Wegovy is on-label, more likely to be covered, and the Wegovy Savings Card applies.
• Waiting on a PAP without enrolling in NovoCare cash-pay first. PAPs take 4-8 weeks; NovoCare ships within days. Start NovoCare while the PAP application processes.

FAQ